International Stem Cell Corporation (QB) (ISCO) 銘柄情報

We've been popping the last couple trading days. What's going on? Other than strong financials haven't found any news.

I am mostly curious as to when they might have their finalized Phase I data ready to share or try and publish, and what their plans going forward are going to be to get a Phase II started.

I've been following this company for a lot of years. I got rid of all my old shares several years ago before they did a big dilution and ate the loss, but bought back in a small number again a couple of years back when it looked like the Phase I was going along well.

I'm guessing that their cash outflow dropped that 98% because they aren't paying for an active Phase I any longer, but the bump in revenue from their subsidiaries was nice. It won't be enough to pay for a Phase II, but it does speak well for keeping the lights on and the lab running in the meantime.

NEWS -- International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022

https://www.accesswire.com/701689/International-Stem-Cell-Corporation-Announces-Strong-Financial-Results-for-the-Quarter-Ended-March-31-2022

Nice to see the Improved Financials out today!!!

It has always amazed me how much under the radar this stock really is. The capitalization value is so low, it just is not followed enough for good or bad news to effect it much. This is quite good news. People in the Parkinson's arena also recognize that any study of efficacy that must be done over a long period can be weighted downward by the tendency for the disease to have naturally progressed at various rates among the trial patients. i.e. - halting deterioration would be a positive sign, near 50% improvement is more than that.

The news is not really out much yet though. Although in the Parkinson's Parkinson's News Today, they put this out today:

https://parkinsonsnewstoday.com/2021/07/01/stem-cell-therapy-shows-safety-potential-efficacy-in-early-clinical-trial/

Painless, you certainly enjoy expounding the news. The obvious question would be: Does it pay well?

NEWS -- International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease

CARLSBAD, CA / ACCESSWIRE / June 30, 2021 / International Stem Cell Corporation (OTCQB:ISCO) (https://www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today successful completion of its dose escalating phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT02452723) evaluating the safety, tolerability and preliminary efficacy of its lead candidate, ISC-hpNSC® for the treatment of Parkinson's disease (PD).

Dr. Andrew Evans, M.D., Director of Movement Disorders at the Royal Melbourne Hospital, the study's principal investigator commented: "The safety evaluation is based on the initial 12 months of safety data from the first cohort (low dose), the second cohort (mid dose), and the third cohort (high dose). In all three cohorts there have been no serious adverse effects related to the transplanted ISC-hpNSC® cells. Based on all data collected in the clinical trial the therapy is considered safe."

In order to gain initial insight into what dose might show the greatest efficacy we have continued observations on a biannual basis of these patients. All the patients in the clinical trial have now completed at least 24 months of total post-operative observations. Patients treated with the mid dose (cohort 2) have been observed for at least 36 months and patients in the low dose group (Cohort 1) have been followed for 48 months post transplantation.

"We are excited about our phase 1 clinical trial results. Patients, followed for over two years after cell transplantation, have reported, on average, improvements in a Parkinson's Disease specific measures, when compared to baseline evaluations. In this context, the results are very encouraging that the ISC-hpNSC® transplanted cells are not only well tolerated, but also may be effective" commented Dr. Russell Kern, ISCO's Executive Vice President and Chief Scientific Officer.

In terms of preliminary efficacy, where scores are compared against baseline before transplantation, we observed a potential dose-dependent response, with an apparent peak effectiveness at our middle dose. The % OFF-Time, which is the time during the day when levodopa medication is not performing optimally and PD symptoms return, decreased an average 47% from the baseline at 12 months post transplantation in cohort 2. This trend continued through 24 months where the %OFF time in the second cohort dropped by 55% from the initial reading. The same was true for % ON-Time without dyskinesia, which is the time during the day when levodopa medication is performing optimally without dyskinesia. The % ON-Time increased an average of 42% above the initial evaluation at 12 months post-transplantation in the second cohort. The %ON result improved in the second cohort to 65% above the baseline in month 24. The quality of life of the patients as measured by the Parkinson's Disease Quality of Life Score-39 (PDQ-39) Summary Index, improved 43% for the second cohort at twelve months post-transplantation. This improved to a 45% better score in cohort 2 at 48 months.

About the clinical study

The Phase 1 clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into patients with Parkinson's disease. The open-label, single center, uncontrolled clinical trial is evaluating three different dose regimens of 30 million to 70 million neural cells. A total of 12 participants with Parkinson's disease were treated. Following transplantation, the patients were monitored for 12 months at specified intervals to evaluate the safety and biologic activity of ISC-hpNSC®. A PET scan was performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr as well as other rating scales. An extension phase of the study will evaluate patients every 6 months for 5 additional years.

About Parkinson's disease

Parkinson's disease is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement related. These symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease. Depression is the most common psychiatric symptom. Parkinson's disease is more common in people over the age of 50. There are no approved treatments that restore the damaged dopaminergic neurons. Medications typically used in the treatment of Parkinson's disease, levodopa and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective, while at the same time frequently producing a complication marked by involuntary writhing movements. There are over 10 million people afflicted with Parkinson's disease, worldwide. In 2013 Parkinson's disease resulted in about 103,000 deaths, globally. In 1990, the death toll recorded was 44,000.

About ISC-hpNSC®

International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are free of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and neuroregeneration to the dying dopaminergic neurons of the recipient Parkinson's disease brain. Additionally, ISC-hpNSC® is safe, well tolerated and has shown not to cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide, through its subsidiary Lifeline Cell Technology (https://www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (https://www.lifelineskincare.com). More information is available at https://www.internationalstemcell.com.

Safe harbor statement

Statements pertaining to anticipated developments, clinical studies expectations, potential additional applications for ISC-hpNSC®, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: mailto://ir@intlstemcell.com

SOURCE: International Stem Cell Corporation

View source version on accesswire.com:
https://www.accesswire.com/653700/International-Stem-Cell-Corporation-Announces-Successful-Completion-of-Its-Phase-1-Clinical-Trial-in-Parkinsons-Disease

$ISCO: monster POP to $0.78


WOW



Nicely played



GO $ISCO

This company has appeared to be very undervalued most of its existance, IMHO. Yes there is some other classes of stock and options that will increase the total effective outstanding share count, but even then it will be fairly low comparatively. This is a development company that has actually produced some income and learned how to make and market their own produces while performing good science and development. More power to them. I hope for their sake and humanity they are even much more successful in the near and long term.

news https://www.otcmarkets.com/stock/isco/news/story?e&id=1933958

International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease
CARLSBAD, CA / ACCESSWIRE / June 30, 2021 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today successful completion of its dose escalating phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT02452723) evaluating the safety, tolerability and preliminary efficacy of its lead candidate, ISC-hpNSC® for the treatment of Parkinson's disease (PD).

Dr. Andrew Evans, M.D., Director of Movement Disorders at the Royal Melbourne Hospital, the study's principal investigator commented: "The safety evaluation is based on the initial 12 months of safety data from the first cohort (low dose), the second cohort (mid dose), and the third cohort (high dose). In all three cohorts there have been no serious adverse effects related to the transplanted ISC-hpNSC® cells. Based on all data collected in the clinical trial the therapy is considered safe."

In order to gain initial insight into what dose might show the greatest efficacy we have continued observations on a biannual basis of these patients. All the patients in the clinical trial have now completed at least 24 months of total post-operative observations. Patients treated with the mid dose (cohort 2) have been observed for at least 36 months and patients in the low dose group (Cohort 1) have been followed for 48 months post transplantation.

"We are excited about our phase 1 clinical trial results. Patients, followed for over two years after cell transplantation, have reported, on average, improvements in a Parkinson's Disease specific measures, when compared to baseline evaluations. In this context, the results are very encouraging that the ISC-hpNSC® transplanted cells are not only well tolerated, but also may be effective" commented Dr. Russell Kern, ISCO's Executive Vice President and Chief Scientific Officer.

In terms of preliminary efficacy, where scores are compared against baseline before transplantation, we observed a potential dose-dependent response, with an apparent peak effectiveness at our middle dose. The % OFF-Time, which is the time during the day when levodopa medication is not performing optimally and PD symptoms return, decreased an average 47% from the baseline at 12 months post transplantation in cohort 2. This trend continued through 24 months where the %OFF time in the second cohort dropped by 55% from the initial reading. The same was true for % ON-Time without dyskinesia, which is the time during the day when levodopa medication is performing optimally without dyskinesia. The % ON-Time increased an average of 42% above the initial evaluation at 12 months post-transplantation in the second cohort. The %ON result improved in the second cohort to 65% above the baseline in month 24. The quality of life of the patients as measured by the Parkinson's Disease Quality of Life Score-39 (PDQ-39) Summary Index, improved 43% for the second cohort at twelve months post-transplantation. This improved to a 45% better score in cohort 2 at 48 months.

About the clinical study

The Phase 1 clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into patients with Parkinson's disease. The open-label, single center, uncontrolled clinical trial is evaluating three different dose regimens of 30 million to 70 million neural cells. A total of 12 participants with Parkinson's disease were treated. Following transplantation, the patients were monitored for 12 months at specified intervals to evaluate the safety and biologic activity of ISC-hpNSC®. A PET scan was performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr as well as other rating scales. An extension phase of the study will evaluate patients every 6 months for 5 additional years.

About Parkinson's disease

Parkinson's disease is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement related. These symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease. Depression is the most common psychiatric symptom. Parkinson's disease is more common in people over the age of 50. There are no approved treatments that restore the damaged dopaminergic neurons. Medications typically used in the treatment of Parkinson's disease, levodopa and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective, while at the same time frequently producing a complication marked by involuntary writhing movements. There are over 10 million people afflicted with Parkinson's disease, worldwide. In 2013 Parkinson's disease resulted in about 103,000 deaths, globally. In 1990, the death toll recorded was 44,000.

About ISC-hpNSC®

International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are free of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and neuroregeneration to the dying dopaminergic neurons of the recipient Parkinson's disease brain. Additionally, ISC-hpNSC® is safe, well tolerated and has shown not to cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide, through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

Safe harbor statement

Statements pertaining to anticipated developments, clinical studies expectations, potential additional applications for ISC-hpNSC®, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.

Contacts:
International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: ir@intlstemcell.com

SOURCE: International Stem Cell Corporation



View source version on accesswire.com:
https://www.accesswire.com/653700/International-Stem-Cell-Corporation-Announces-Successful-Completion-of-Its-Phase-1-Clinical-Trial-in-Parkinsons-Disease

© Copyright 2021 ACCESSWIRE. All Rights Reserved.

I still purchase skin care product from them. The best I've ever used.
https://lifelineskincare.com/

I'd really like to hear about Parkinson's results.










Message in reply to:

Is this company still around?

Is this company still around?

They have been quite silent compared to previous years. I hope they are just conserving cash and maintaining basic and profitable lines going.

On the research end they indicated the following in their most recent report: “””””” In April 2019, we announced the completion of subject enrollment, with the 12th subject receiving a transplantation of the highest dose of cells. There have been no safety signals or serious adverse effects seen to date as related to the transplanted ISC-hpNSC® cells. We anticipate providing full results of the active and follow up periods of the phase I clinical study in the second quarter of 2021.”

They have an annual meeting coming up that will be virtual only due to ongoing Covid activity. Their notice says; “””This year’s annual meeting of stockholders will be held on Wednesday, June 9, 2021, at 10:00 a.m. Pacific Time. Due to the public health concerns arising from the COVID-19 pandemic, the Annual Meeting will be a completely virtual meeting of stockholders. You can attend the Annual Meeting by visiting www.proxydocs.com/ISCO “”””

Anything NEWS? Anything

Held for 3 years, nice to see the upturn, I am hoping that insiders are buying!
67% of the shares out are held by insiders , looking for great news to hit the wires. Good luck all.

All kinds of junk/defunct companies have moved in the past few weeks. ISCO is revenue producing and is way overdue for a nice run!

1s next week!

Thanks!

I sold out what I held right before the last R/s. Bought back in a bit at about $1.50 a share a year + back,.... and then watched it tank for a while since.

If I can find any actual news,... might buy more. I have not seen any assessments of their Phase I work in Australia for Parkinson's Disease,... but that data should be finalized by now I would think.

I have a similar problem. I need $30/share to get back everything I put in after the Reverse Split.

I wrote this stock off and was not planning on doing anything with this ticker. The only reason I even noticed the ticker was because of the recent gains. I am curious will anyone add shares and try to average down the cost? Or just wait for the price to increase?

Any idea what is driving this? I can't find any news in the places I usually track.

tomorrow much more chatter on this!

1s are coming!

I need $55/sh to get back everything I put in after the RS. LOL

They still have Lifeline skin care plus a bunch of patents. Once it starts trading in the upper 90s. Watch out

I hope. I thought this was dead

The start of an upswing!

Been stuck in this for years. Nice to see a little action. Most in a long one.

low float and 68% held by insiders could go to 50 dollars a share short term.

Interesting new study:

Parkinsons may start before birth iPSCs

Interesting new study:

insert-text-here

https://www.cedars-sinai.org/newsroom/parkinsons-disease-may-start-before-birth/

Nice move up the last 7 days.

Wonder what is the engine pushing this up. It is obviously more than just a normal bounce off of the lows. Got in this AM and am thinking of doubling my shares.

Eischelman! Could it be? or is it just a response to the undervalued state of ISCO?

That is a red herring if I ever saw one. Very little if anything to do with ISCO.

Russian journals retract more than 800 papers after ‘bombshell’ investigation


https://www.sciencemag.org/news/2020/01/russian-journals-retract-more-800-papers-after-bombshell-investigation

Nice activity and pop.

20K for the Eischelman papers? Are the advancing for ISCO?

Whoaa! $0.352 - New 52 week low!

$0.39 - New 52 week low!

$0.45 - New 52 week low!

$0.4862 - New 52 wk low!

$0.59 - New 52 week low!

$0.6601 - New 52 week low!

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)


Date : 08/14/2019 @ 5:07PM
Source : Edgar (US Regulatory)
Stock : International Stem Cell Corp. (QB) (ISCO)
Quote : 0.71 0.0 (0.00%) @ 1:11PM

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
Print
Alert
SEC File Number: 0-51891

CUSIP Number: 460378 201







UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549





FORM 12b-25





NOTIFICATION OF LATE FILING



(Check One)
? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q

? Form 10-D ? Form N-SAR ? Form N-CSR

For Period Ended: June 30, 2019
? Transition Report on Form 10-K
? Transition Report on Form 20-F
? Transition Report on Form 11-K
? Transition Report on Form 10-Q
? Transition Report on Form N-SAR
For the Transition Period Ended:



Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:







PART I — REGISTRANT INFORMATION

International Stem Cell Corporation

(Full Name of Registrant)

N/A

(Former Name if Applicable)

5950 Priestly Drive

(Address of Principal Executive Office ( Street and Number ))

Carlsbad, California 92008

(City, State and Zip Code)





PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)



? (a)
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;



(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and



(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

International Stem Cell Corporation (the “Company”) has determined it will not be able to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense. The Company expects that the Form 10-Q will be filed no later than the fifth calendar day following the prescribed due date.

The Form 10-Q cannot be filed by the prescribed due date because the Registrant is experiencing delays in the compilation of certain financial and other information required to be included in the Form 10-Q and responding to and resolving questions relating to the review of that information.





PART IV — OTHER INFORMATION



(1)
Name and telephone number of person to contact in regard to this notification



Sophia Garnette (760) 940-6383
(Name) (Area Code) (Telephone Number)


(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ? Yes ? No



(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ? Yes ? No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.







International Stem Cell Corporation

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.



Date

August 14, 2019 By:
/s/ Sophia Garnette


Sophia Garnette

Vice President, Legal

Affairs and Operations

Item 4.01. Changes in Registrant’s Certifying Accountant.


https://www.sec.gov/Archives/edgar/data/1355790/000119312519206987/d784689d8k.htm


Item 4.01. Changes in Registrant’s Certifying Accountant.

(a) On July 25, 2019, the Audit Committee of the Board of Directors of International Stem Cell Corporation (the “Company”) elected to conclude the Company’s 8-year engagement with its independent registered public accounting firm Mayer Hoffman McCann P.C. (“MHM”).

MHM’s audit reports on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2018 and 2017 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except for the inclusion of an explanatory paragraph regarding the Company’s ability to continue as a going concern.

During the fiscal years ended December 31, 2018 and 2017, and the subsequent interim period through July 25, 2019, there were (i) no disagreements between the Company and MHM on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, any of which, if not resolved to MHM’s satisfaction, would have caused MHM to make reference thereto in its reports, and (ii) except as noted in the following paragraph, no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K.

As previously disclosed in the Company’s Annual Reports on Form 10-K for the fiscal year ended December 31, 2017 (the “2017 10-K”) and for the fiscal year ended December 31, 2018 (the “2018 10-K”), the Company reported material weaknesses (the “Material Weaknesses”) in its internal control over financial reporting. In particular, as of December 31, 2017, the Company concluded its disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting related to the accounting for and disclosure of equity transactions. As of December 31, 2018, the Company concluded that its disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting including the areas of financial reporting and technical accounting, disclosures of equity, complex, non-routine, and significant transactions, and adoption of new accounting standards, collectively resulting from lack of continuity and sufficient accounting and finance resources. MHM was not required to, and did not, audit the Company’s internal control over financial reporting. The Audit Committee and management discussed the Material Weaknesses with MHM. The Company has authorized MHM to respond fully and without limitation to any inquiries of BDO USA, LLP (“BDO”), the Company’s successor independent registered public accounting firm, concerning the Material Weaknesses.

The Company provided MHM with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that MHM furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made herein. A copy of MHM’s letter dated July 26, 2019, is filed as Exhibit 16.1 hereto.

(b) Following a selection process that evaluated several potential successor independent registered public accounting firms, on July 25, 2019, the Audit Committee approved the appointment of BDO as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2019. During the fiscal years ended December 31, 2018 and 2017, and the subsequent interim period through July 25, 2019, neither the Company nor anyone on its behalf consulted with BDO regarding (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that BDO concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

16.1 Letter of Mayer Hoffman McCann P.C. to the Securities and Exchange Commission, dated July 26, 2019.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



International Stem Cell Corporation
By: /s/ Sophia Garnette
Sophia Garnette
Vice President Legal Affairs and Operations
Dated: July 30, 2019

So KarinCA, tell us

when you stated that

"ISCO isn't a scam company"

what exactly did you mean?

because, have you read this?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149987120



Why ISCO is running trials in Australia.

ISCO isn't a scam company. They have two subsidiaries bringing in revenue. But, research and trials are very expensive. Cost is why many companies are running clinical trials in Australia. Go to the links I've provided rather than just reading the titles.

I'm sure you've heard of astrazeneca. Here's their take on doing trials in Australia.
https://www.astrazeneca.com.au/sustainability/About-us-research-development.html
Quote:
In partnership with doctors in Australia we focus our skills and resources on getting life-changing medicines to patients as quickly, safely and efficiently as possible. We are currently conducting research to develop new medicines in the following disease areas:

To find out more about clinical trials in Australia, please visit the dedicated Australian Government website www.australianclinicaltrials.gov.au

**********

HTTPS://WWW.OUTSOURCING-PHARMA.COM/ARTICLE/2019/04/29/AUSTRALIA-S-CLINICAL-TRIALS-INDUSTRY-IS-EXPERIENCING-UNPRECEDENTED-SUPPORT
Quote:
Australia’s clinical trials industry is experiencing ‘unprecedented support’
29-Apr-2019 By Melissa Fassbender

The Australian Government commits $100m to support rural, regional, and remote clinical trials – recognizing the importance of a “vibrant clinical trial ecosystem in underpinning a world-class health care system,” says industry expert.


**********

Australia: Preferred Destination for Early Phase Clinical Trials
https://ww3.frost.com/files/6514/7374/3781/Novotech_WP_20160701_v2.1.pdf

**********

As I said earlier, dilution has been the main problem here. Not unheard of in biotech. Biotech is very risky for early investors and I got involved way too early with this one. But, that is my fault, not the company's fault. It's been off my radar for awhile now, but, I'm watching again for the upcoming trial results.

Who owns Cascado AG and what is their relationship with ISCO, its CEO Andrey Semechkin and its CSO Russell Kern?


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149987120

Timber! Massive hits at bid drop the price down to $0.77

how much further will it drop this week?

next week?

below .60?

below .50?

ISCO – The Russians, The Panama Papers, The Latvians – Follow The Money


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149987115

It's coming back up. Hope you took advantage of the dip.